Companies · Biotech

Acoustic Wave Cell Therapy, Inc.

VAN NUYS · Biotech · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Acoustic Wave Cell Therapy, Inc. — recommendation, valuation, rhythm, risks.
$20.5M
Total raised · real
3
Rounds
1.3×
Latest step-up
Top 10%
Sector rank · raised
Series A
Latest stage · inferred · Thu Aug 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Acoustic Wave Cell Therapy, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.68× the median modeled value of Series A Biotech companies in 2022–2024 (12 peers) — value vs value, same stage and era.
At-risk
  • Last raise 2.9 yr ago; this sector typically re-raises about every 11 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech

Acoustic Wave Cell Therapy, Inc. is one of 233 Biotech companies tracked from VAN NUYS. By capital raised it ranks among the largest (ahead of 91% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

biotech

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
17
Investors (latest)
2023-08-03
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeed · 2016-09-06 Raised $1.9M (real) Modeled valuation $83M (est)$1.9M$83MSeed2016Series A · 2018-04-17 Raised $8.2M (real) Modeled valuation $297M (est)$8.2M$297MSeries A2018Series A · 2023-08-03 Raised $10M (real) Modeled valuation $85M (est)$10M$85MSeries A2023+$8.2M+$10MCumulative $21M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.9M · 2016
Series A$8.2M · 2018
Series A extension$10.4M · 2023

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$85.0M
Base estimate est.
$11.4M
Conservative case
$226.9M
Upside case
$47.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $83.3M · 2016-09-062016Series A · modeled $296.8M · 2018-04-17Series A · modeled $85.0M · 2023-08-032023
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
2.9 yr
Elapsed time used
2.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
41 mo
Avg between rounds
$3.0M/yr
Capital velocity
9.8 yr
On record since
2016
First round
3
Rounds on file
How it compares to the market

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.6× above median
This company$20.5M
Sector median$7.8M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.7× above median
This company$10.4M
Sector median$6.0M
Modeled value — vs sector median (estimate, all stages) 1.5× above median
This company$85.0M
Sector median$56.2M

Raised more than 91% of sector peers (real $). Modeled value above 85% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #4 of 12.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Epsilon3, Inc. · Series A Raised $15.0M · modeled $217.3M (est)Salish Bioscience Inc. · Series A Raised $7.0M · modeled $109.6M (est)HB Biotech, Inc. · Series A Raised $7.8M · modeled $87.8M (est)Mindstate Design Labs, Inc. · Series A Raised $12.7M · modeled $56.2M (est)Nurture Genomics, Inc. · Series A Raised $4.3M · modeled $53.5M (est)Talus Bioscience, Inc. · Series A Raised $9.4M · modeled $47.7M (est)Abacus Bioscience Inc. · Series A Raised $4.4M · modeled $46.6M (est)Ark Biotech Inc. · Series A Raised $21.7M · modeled $46.0M (est)Escalante Bioscience, Inc. · Series A Raised $6.7M · modeled $38.1M (est)Zivo Bioscience, Inc. · Series A Raised $14.6M · modeled $34.1M (est)Unite Genomics, Inc. · Series A Raised $7.8M · modeled $14.9M (est)Acoustic Wave Cell Therapy, Inc. (this company) Raised $20.5M · modeled $85.0M (est)Acoustic Wave Cell Therapy, Inc.
CompanyStageRaised · realValue · estvs peer med.
Epsilon3, Inc.Series A$15.0M$217.3M4.29×
Salish Bioscience Inc.Series A$7.0M$109.6M2.17×
HB Biotech, Inc.Series A$7.8M$87.8M1.74×
Acoustic Wave Cell Therapy, Inc. this companySeries A$20.5M$85.0M1.68×
Mindstate Design Labs, Inc.Series A$12.7M$56.2M1.11×
Nurture Genomics, Inc.Series A$4.3M$53.5M1.06×
Talus Bioscience, Inc.Series A$9.4M$47.7M0.94×
Abacus Bioscience Inc.Series A$4.4M$46.6M0.92×
Ark Biotech Inc.Series A$21.7M$46.0M0.91×
Escalante Bioscience, Inc.Series A$6.7M$38.1M0.75×
Zivo Bioscience, Inc.Series A$14.6M$34.1M0.67×
Unite Genomics, Inc.Series A$7.8M$14.9M0.29×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.9M2016-09-06$9.4M$83.3M90%
Series A$8.2M2018-04-17$37.3M$296.8M90%
Series A$10.4M2023-08-03$47.4M$85.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.9M2016-09-06
    • First recorded raise — entered as Seed.
    • 5 investors on this round.
  2. Series A$8.2M2018-04-17
    • Raised again after 19 mo — slower than the ~11 mo sector norm.
    • Round 4.4× larger than the prior — scaling up.
    • 29 investors on this round.
  3. Series A$10.4M2023-08-03
    • Raised again after 64 mo — slower than the ~11 mo sector norm.
    • Round roughly the size of the prior one.
    • 17 investors on this round.
Intelligence
2027 ~Q1
Modeled next raise · ~41mo cadence
$13.2M
Modeled next size est.range $10.4M$21.2M
1.3×
Last step-up
$3.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
PAUL MACCASKILL1 other2016-09
CHARLES ENGLES2016-09
CHIAHUI WANG2023-08
TOM LUE2016-09
Registry & provenance

Acoustic Wave Cell Therapy, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1706636
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Transplant Genomics Inc.BiotechSeries A$20.6M$288.4Msame sector · same stage
Ark Biotech Inc.BiotechSeries A$21.7M$46.0Msame sector · same stage
CHD Bioscience, Inc.BiotechSeries A$18.7M$3.3Msame sector · same stage
Epsilon3, Inc.BiotechSeries A$15.0M$217.3Msame sector · same stage
Pure Bioscience, Inc.BiotechSeries A$28.8M$12.2Msame sector · same stage
Zivo Bioscience, Inc.BiotechSeries A$14.6M$34.1Msame sector · same stage
Tamarind Bio, Inc.BiotechSeries A$13.6M$47.6Msame sector · same stage
Mindstate Design Labs, Inc.BiotechSeries A$12.7M$56.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Biocellular Medical Investments LLCHealthtechPre-Seed$421K80%
Biowave CorpOther Health CareSeed$33.0M79%
Seismic Therapeutic, Inc.Biotech / PharmaSeries D+$1.9B78%
Sound Pharmaceuticals IncBiotechnologySeries A$304.0M77%
Audio Bionics International Inc.Other Health CarePre-Seed$30.8M77%
Sonara Health, Inc.HealthtechSeries A$28.3M77%
First Wave Bio, Inc.BiotechnologySeed$116.2M77%
Waveclear, Inc.BiotechnologySeed$8.4M76%
Frequently asked
How much funding has Acoustic Wave Cell Therapy, Inc. raised?
Acoustic Wave Cell Therapy, Inc. has raised approximately $20.5M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Acoustic Wave Cell Therapy, Inc.'s estimated valuation?
Provath's modeled valuation for Acoustic Wave Cell Therapy, Inc. is approximately $85.0M (modeled range $11.4M–$226.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Acoustic Wave Cell Therapy, Inc. at?
Acoustic Wave Cell Therapy, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Aug 03.
What does Acoustic Wave Cell Therapy, Inc. do and where is it based?
Acoustic Wave Cell Therapy, Inc. operates in the Biotech sector, based in VAN NUYS.
Explore related

See where Acoustic Wave Cell Therapy, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Acoustic Wave Cell Therapy, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.